RecruitingNot ApplicableNCT05038462

Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction


Sponsor

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Enrollment

304 participants

Start Date

Jan 18, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Lactoferrin and DHA and Placebo for people with fetal growth retardation and intrauterine growth restriction. The study is currently recruiting participants at 6 locations. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTLactoferrin and DHA

The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily

OTHERPlacebo

Product with the same physical appearance and taste as the main intervention but without therapeutic effect


Locations(6)

Hospital Clínic de Barcelona

Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Hospital del Mar

Barcelona, Spain

Hospital Dexeus-Quirón

Barcelona, Spain

Hospital Sant Joan de Déu

Esplugues de Llobregat, Spain

Hospital General del Hospitalet

L'Hospitalet de Llobregat, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05038462


Related Trials